U.S. Central Nervous System Therapeutic Market Size, Share and Trends 2026 to 2035

Revenue, 2025

USD 43.79 Bn

Forecast Year, 2035

USD 100.94 Bn

CAGR, 2026 - 2035

8.71%

Report Coverage

U.S.

The U.S. central nervous system therapeutic market size was evaluated at USD 43.79 billion in 2025 and is expected to attain around USD 100.94 billion by 2035, registering a CAGR of 8.71% from 2026 to 2035. The Market is driven by the increasing rates of neurological and psychiatric disorders, an older population, greater awareness of mental health, and advancements in drug delivery and biotechnology.

U.S. Central Nervous System Therapeutic Market Statical Scope

CNS therapeutics in the U.S. are crucial as they focus on complex and debilitating conditions such as Alzheimer's, Parkinson's, multiple sclerosis, and major depression. They tackle significant public health challenges, improve the quality of life for patients, and promote medical innovation, even with the challenges posed by the blood-brain barrier. Millions of Americans deal with chronic neurological and psychiatric issues. Effective treatments are designed to slow cognitive decline, restore motor function, and alleviate severe pain.

Proper management reduces the long-term need for institutional and family care. The development of CNS drugs advances biotechnology, especially in areas like neuroprotection and gene or stem cell therapies. Research is leading to new drug-delivery methods that can overcome the blood-brain barrier. Substantial investments in the U.S. and globally support specialized clinical trials and the pharmaceutical industry.

U.S. Central Nervous System Therapeutic Market, By Disease, 2025 (%)

• Neurovascular Diseases - The neurovascular diseases segment, with a share of 15.00% in 2025, which includes conditions such as stroke and cerebral aneurysms, plays a crucial role in the U.S. Central Nervous System (CNS) Therapeutic Market. This is due to high patient morbidity, an aging population, costly acute care requirements, and progress in interventional clot-retrieval devices and targeted vascular medications.
• Mental Health - The mental health segment, with a share of 31.00% in 2025, leads the U.S. Central Nervous System (CNS) Therapeutic Market, fueled by a large patient base dealing with depression, anxiety, and PTSD, significant prescription rates for antidepressants, and increasing insurance coverage alongside diminishing social stigma.
• Neurodegenerative Diseases - The neurodegenerative diseases segment, with a share of 27.00% in 2025, is important in the Central Nervous System (CNS) therapeutics market due to a rapidly aging U.S. population, high prevalence of diseases like Alzheimer's and Parkinson's, and a significant shift towards high-value, disease-modifying biologics and monoclonal antibodies.
• CNS Trauma - The Central Nervous System (CNS) trauma segment, with a share of 8.00% in 2025, is vital in the U.S. CNS therapeutic market as it needs high-acuity emergency and inpatient care, addresses life-threatening secondary brain and spinal injuries, and drives intensive research and development in neuroprotection, neuroinflammation management, and long-term neurorecovery technologies.
• CNS Cancer - The Central Nervous System (CNS) cancer segment, with a share of 6.00% in 2025, is crucial in the U.S. CNS therapeutic market as it fosters high-value precision oncology advancements, tackles aggressive malignant tumors like glioblastoma that have poor prognoses, and needs substantial R&D investment to navigate complex drug delivery challenges such as the blood-brain barrier.
• Infectious Diseases - The infectious diseases sector, with a share of 5.00% in 2025, within the U.S. Central Nervous System (CNS) therapeutic market focuses on serious, life-threatening illnesses such as bacterial meningitis, encephalitis, and neuro-HIV. It is crucial because of the high mortality rates, the need for emergency care, and the persistent risks of pathogen resistance.

Competitive Landscape

The U.S. central nervous system (CNS) therapeutic market is highly competitive, with major companies targeting psychiatric disorders, neurodegenerative diseases, and multiple sclerosis. Key players include AbbVie, Biogen, Johnson & Johnson, Eli Lilly, and Novartis, all of which invest significantly in biologics and precision medicine.

• AbbVie Inc. leads in revenue due to its strong focus on managing psychiatric and neurological symptoms.
• Biogen Inc. concentrates on neurodegenerative diseases, especially multiple sclerosis and new treatments for Alzheimer's disease.
• Johnson & Johnson Services, Inc. is a leader in neuropsychiatry, offering long-acting injectable antipsychotics for schizophrenia and bipolar depression.
• Eli Lilly and Company is dedicated to migraine prevention and advanced monoclonal antibody therapies for early-stage Alzheimer's disease.
• Novartis AG has a wide range of products for multiple sclerosis, migraine, and advanced RNA-based neuromuscular treatments.

Segments Covered in the Report

By Disease

• Neurovascular Diseases
• Mental Health
• Neurodegenerative Diseases
• CNS Trauma
• CNS Cancer
• Infectious Diseases
• Others